Compare LFMD & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | OBIO |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | 384 | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 240.7M |
| IPO Year | N/A | 2020 |
| Metric | LFMD | OBIO |
|---|---|---|
| Price | $4.55 | $4.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $9.14 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 907.2K | 228.5K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | $17.52 | N/A |
| Revenue Next Year | $18.73 | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $2.60 | $2.20 |
| 52 Week High | $14.43 | $5.42 |
| Indicator | LFMD | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 50.18 |
| Support Level | $3.39 | $3.77 |
| Resistance Level | $4.74 | $4.18 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 31.44 | 55.26 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.